Both difenoconazole and propiconazole belong to FRAC Group 3. They inhibit the C14 demethylation process in the sterol biosynthesis of pathogenic fungi, thereby disrupting the normal formation and function of the cell membrane.
Both active ingredients are triazole-based DMI fungicides. Although they may differ in specific pathogen activity, physicochemical properties, and application characteristics, they share the same primary mode of action.
This combination can be used for the development of formulations targeting certain susceptible fungal diseases; however, it should not be simply viewed as a fungicide blend with two different modes of action.
For pathogens that have already shown reduced susceptibility to DMIs, the risk of cross-resistance must also be considered. The formulation itself does not guarantee that existing resistance issues can be overcome.
When purchasing, special attention should be paid to the suspension stability of the SC formulation, active ingredient content, registration status in target markets, and specific disease control applications.
Supply Information
MaFa Agro provides supply consultations for Difenoconazole 15% + Propiconazole 15% SC products and can coordinate packaging sizes, brand labels, and product technical documentation according to customer needs.
We assist importers and distributors in confirming formulation specifications, sample requirements, and export procurement terms.